$CTSO

Chan Phillip P. purchased $105K of CTSO

Chan Phillip P. (Chief Executive Officer) purchased 261,469 shares of Cytosorbents Corp (CTSO) at an average of $0.40 ($0.40–$0.43, $0.10M total) across 2 trades over 2026-06-12 to 2026-06-15.

Original reporting
SEC EDGAR · Chan Phillip P.
Published Jun 15, 2026, 10:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CTSO
Bullish
medium confidence
Mentioned
$CTSO
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTSOBullishLow
01

Why it matters

The newest information is the CEO’s open-market purchase details (shares, price range, total value) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may treat this as a small sentiment input, but it does not replace fundamental catalysts (earnings, trial results, contracts, or financing).

03

What to watch

The article notes no 10b5-1 plan, but it does not disclose motivations, option exercises, or whether additional insider activity occurred around the same period.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-15 (SEC Form 4) for trades dated 2026-06-12 to 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Cytosorbents Corp (CTSO).

Company-level read

Ticker impact

$CTSOBullishMedium confidence
Context

Cytosorbents CEO Chan Phillip P. bought $104.9K of CTSO shares in two open-market trades (261,469 shares) per Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or operational news.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no new business development—only the size, price range, and that it was not under a pre-arranged 10b5-1 plan.

Market effects

No sector-wide read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

CEO buying can be driven by personal liquidity needs or diversification rather than a forward-looking view; without accompanying operational news, price reaction may be muted.

Key entities

  • Cytosorbents Corp

    Subject of the Form 4 insider transaction disclosure.

  • Chan Phillip P.

    CEO and officer/director who purchased CTSO shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.